Compound Detail
CHEMBL11359
CISPLATIN 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
No structure available
Basic Information
| ChEMBL ID | CHEMBL11359 |
| Name | CISPLATIN |
| Phase | Approved |
| Structure Type | NONE |
| Therapeutic | ✓ Yes |
0
Targets
0
Activities
0
Assay Types
0
PK Parameters
0
Publications
19
Known Names
20
Indications
1
Mechanisms
Molecular Properties
300.1
MW (Da)
Drug Information
| Molecule Type | Small molecule |
| First Approval | 1978 |
| Availability | Prescription |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| DNA inhibitor | INHIBITOR | DNA | ✓ | ✓ |
Indications
Neoplasms Neoplasms Adenocarcinoma Adenocarcinoma Adenocarcinoma of Lung Adrenal Cortex Neoplasms Anemia Anus Neoplasms Biliary Tract Neoplasms Biliary Tract Neoplasms Brain Neoplasms Brain Neoplasms Breast Neoplasms Breast Neoplasms Breast Neoplasms Carcinoma Carcinoma Carcinoma, Embryonal Carcinoma, Hepatocellular Carcinoma, Non-Small-Cell Lung
ATC Classification
L01XA01
cisplatin
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: ANTINEOPLASTIC AGENTS
Drug Warnings
Black Box Warning
nephrotoxicity
Black Box Warning
immune system toxicity
Black Box Warning
respiratory toxicity
Black Box Warning
hematological toxicity
Black Box Warning
cardiotoxicity
Black Box Warning
gastrointestinal toxicity
Black Box Warning
vascular toxicity
Data from ChEMBL 36 via Core Engine